Galcanezumab for the prevention of high frequency episodic and chronic migraine in real life in Italy: a multicenter prospective cohort study (the GARLIT study)

BACKGROUND: The clinical benefit of galcanezumab, demonstrated in randomized clinical trials (RCTs), remains to be quantified in real life. This study aimed at evaluating the effectiveness, safety and tolerability of galcanezumab in the prevention of high-frequency episodic migraine (HFEM) and chron...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Headache Pain
Egile Nagusiak: Vernieri, Fabrizio, Altamura, Claudia, Brunelli, Nicoletta, Costa, Carmelina Maria, Aurilia, Cinzia, Egeo, Gabriella, Fofi, Luisa, Favoni, Valentina, Pierangeli, Giulia, Lovati, Carlo, Aguggia, Marco, d’Onofrio, Florindo, Doretti, Alberto, Di Fiore, Paola, Finocchi, Cinzia, Rao, Renata, Bono, Francesco, Ranieri, Angelo, Albanese, Maria, Cevoli, Sabina, Barbanti, Piero
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer Milan 2021
Gaiak:
Research Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8091153/
https://ncbi.nlm.nih.gov/pubmed/33941080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s10194-021-01247-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak